Geert Abraham Huls, Michael W. M. Kühn, Paresh Vyas, Hartmut Döhner, Bob Lowenberg, Patrycja Gradowska, Samiyeh Price, Angela R. Smith, Stéphane de Botton, Christian Récher, Jordi Esteve, Adriano Venditti, Thomas Pabst, Vladimir Lazarevic, Kimmo Porkka, Dimitri Breems, Andrius Zucenka, Elisabeth Koller, Andrew H. Wei, Joshua F. Zeidner. "A phase 3 study of revumenib plus venetoclax/azacitidine in adults with newly diagnosed
NPM1
-mutated or
KMT2A
-rearranged acute myeloid leukemia ineligible for intensive chemotherapy (EVOLVE-2/HO177/AMLSG35-24/ACT-HOV-AML-002).." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.tps6600